drugset / Trial / NCT04857372
A Phase I Study of IAG933 in Patients With Advanced Mesothelioma and Other Solid Tumors
Non-randomizedSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to characterize the safety and tolerability of IAG933 in patients with mesothelioma, NF2/LATS1/LATS2 mutated tumors and tumors with functional YAP/TAZ fusions and to identify the maximum tolerated dose and/or recommended dose.
Timeline
- Start
- 2021-10-21
- Primary completion
- 2027-01-07
- Completion
- 2027-01-08
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IAG933 | Unknown | — | Oral |